Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Director Kevin Bitterman of Disc Medicine, Inc. (NASDAQ:IRON) sold a total of 32,174 shares of common stock on August 13 and 14, 2025. The sales, executed under a prearranged Rule 10b5-1 trading plan, totaled $1.96 million. The biotech company, currently valued at $2.08 billion, trades at $59.86 per share, with analyst targets ranging from $85 to $132.
On August 13, Bitterman sold 24,962 shares at a weighted average price of $61.15, with prices ranging from $60.95 to $61.615. Following this, on August 14, he sold 7,212 shares at a weighted average price of $60.99, with prices ranging from $60.95 to $61.11. InvestingPro analysis shows the stock has demonstrated strong returns over the last three months, though price movements remain volatile. Discover 8 more exclusive insights with InvestingPro.
Following these transactions, Bitterman indirectly holds 592,908 shares through Atlas Venture Opportunity Fund I, LP, 420,549 shares through Atlas Venture Opportunity Fund II, LP and 51,000 shares through Atlas Venture Fund XII, L.P. Bitterman disclaims beneficial ownership of these shares except to the extent of his pecuniary interest. The company maintains a FAIR financial health score according to InvestingPro’s comprehensive analysis.
In other recent news, Disc Medicine has announced plans to submit a New Drug Application (NDA) for bitopertin, intended for the treatment of erythropoietic protoporphyria (EPP), in October 2025. The submission will be under the FDA’s accelerated approval pathway, following positive feedback from a pre-NDA meeting with the agency. Additionally, Truist Securities has initiated coverage on Disc Medicine, assigning a Buy rating with a price target of $86, highlighting the company’s promising hematological disorders pipeline. Raymond James also reiterated its Strong Buy rating, maintaining a price target of $89, despite Bristol Myers Squibb’s luspatercept trial narrowly missing its primary endpoint. Furthermore, Disc Medicine has appointed Nadim Ahmed to its board of directors, with Ahmed bringing experience from his role as President and CEO of Cullinan Therapeutics. These developments indicate active progress and strategic changes within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.